A first-in-man study of the bioheart sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease:one-year clinical and imaging outcomes

摘要

Background Current studies,including randomized trials and meta-analyses evaluating clinical Results of bioresorbable scaffold(BRS),have raised concerns about the first-generation device with thicker struts and limited expansion capability.Newer BRS with thinner struts and improved deliverability are expected to enhance safety and efficacy profile.Bioheart(Bio-Heart,Shanghai,China)BRS is constructed from a PLLA backbone coated with a PDLLA layer eluting sirolimus.Sixmonth Results have proved preliminary safety and effectiveness of the Bioheart BRS in patients with single de novo coronary artery lesions.We sought to report serial intracoronary imaging findings at 1 year.